The 2026 European Association for the Study of Diabetes ("EASD") annual meeting in Milan has become the stage for a fierce data duel between Eli Lilly LLY and Novo Nordisk NVO. Both pharma giants unveiled new clinical evidence to bolster their positions in the booming weight-loss drug market. Lilly presented full Phase 3 data for its triple-G drug retatrutide, showing that 34.9% of patients on the highest dose lost at least 25% of their body weight, alongside a new combination drug, EloraTZP, that delivered up to 23.3% weight loss in patients with obesity and type 2 diabetes. Novo countered this with real-world data suggesting that Ozempic is associated with a 6% lower risk of major cardiovascular events compared with Lilly's Mounjaro.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.